P2P Lending, Bonds and Finance News
Biotech is one of the most promising sectors of the economy that bring you growth, risk, and excitement. For those investors who like to delve deeper into risky ventures that could change the medical world as we know it, biotech is the right place to … [Read more...]
US Pharma company Johnson & Johnson was recently directed by the Delhi High Court to pay ₹25 lakh each to all the patients who received their faulty implants. The company confirmed that it had started the disbursement in a statement. What is … [Read more...]
German Pharma Company Bayer AG today welcomed a US judge’s call to reduce $2 billion damages award in a case related to its glyphosate-based weed killer. US judge overturns the order A jury had previously concluded that the glyphosate-based … [Read more...]
Novartis International AG recently posted its financial results for the second quarter of 2019. The company experienced stronger sales during the three-month period alongside double-digit growth in its core operating income. Key highlights from … [Read more...]
Optum by UnitedHealth Group is launching a new partnership with a small Northern Californian hospital operator to help it compete with bigger rivals. Helping hospitals stay independent UnitedHealth’s Optum is striking a new deal with John Muir … [Read more...]
AbbVie recently completed the acquisition of a three-year-old Seattle-based startup Mavupharma. The acquisition gives the company access to the startup’s STING fever program. The company has become the latest in the line of pharma and biotech … [Read more...]
Belgian biotech firm Galapagos has struck a new deal with Gilead Sciences where the latter will acquire a larger stake for $5.1 billion. The deal is the largest yet by new Gilead CEO Daniel O’Day. A long-term perspective Gilead Sciences and … [Read more...]
An experimental HIV vaccine developed by Johnson & Johnson is ready to be tested on thousands of humans in the US and Europe. It could include the first immunization against the disease. New study regimen for gay men The first regimen of … [Read more...]
The Banner Alzheimer’s Institute alongside Amgen and Novartis has decided to halt the trials of BACE1 inhibitor CNP520 (umibecestat). The decision comes after the drug led to the worsening of symptoms in some patients. New Alzheimer’s drug … [Read more...]
The U.S. Food and Drug Administration (USFDA) has kicked off review of Sanofi’s isatuximab for the treatment of relapsed/refractory multiple myeloma. The drug will follow a standard 10-month review process, and the FDA will decide its fate by April … [Read more...]
